ArticleOncogene2013
A mouse model with T58A mutations in Myc reduces the dependence on KRas mutations and has similarities to claudin-low human breast cancer.
Article in Oncogene, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 25 citations in OpenAlex.
- Insights from Genomic Sequencing of Preclinical Breast Cancer Models Establish Human Parallels to Increase Therapeutic Applicability.Journal of mammary gland biology and neoplasia · 2026Review
- Activation of Kv11.1 potassium channel suppresses non-small cell lung cancer growth by promoting c-Myc degradation.Communications biology · 2025Article
- Dormant tumors circumvent tumor-specific adaptive immunity by establishing a Treg-dominated niche via DKK3.JCI insight · 2023Article
- lncRNA MALAT1 participates in metformin inhibiting the proliferation of breast cancer cell.Journal of cellular and molecular medicine · 2021Article
- HAS3-induced extracellular vesicles from melanoma cells stimulate IHH mediated c-Myc upregulation via the hedgehog signaling pathway in target cells.Cellular and molecular life sciences : CMLS · 2020Article
- E2F1 Drives Breast Cancer Metastasis by Regulating the Target Gene FGF13 and Altering Cell Migration.Scientific reports · 2019Article
- A mouse model featuring tissue-specific deletion of p53 and Brca1 gives rise to mammary tumors with genomic and transcriptomic similarities to human basal-like breast cancer.Breast cancer research and treatment · 2019Article
- p53-independent role of MYC mutant T58A in the proliferation and apoptosis of breast cancer cells.Oncology letters · 2019Article
- Gene and Biochemical Pathway Evaluation of Burns Injury via Protein-Protein Interaction Network Analysis.Galen medical journal · 2019Article
- Using gene expression data to direct breast cancer therapy: evidence from a preclinical trial.Journal of molecular medicine (Berlin, Germany) · 2018Review
- Histological subtypes of mouse mammary tumors reveal conserved relationships to human cancers.PLoS genetics · 2018Article
- Article
- Claudin proteins, outside-in signaling, and carcinogenesis.Pflugers Archiv : European journal of physiology · 2017Review
- Deubiquitinase USP13 maintains glioblastoma stem cells by antagonizing FBXL14-mediated Myc ubiquitination.The Journal of experimental medicine · 2017Article
- Characterizing genomic alterations in cancer by complementary functional associations.Nature biotechnology · 2016Article
- Conserved E2F mediated metastasis in mouse models of breast cancer and HER2 positive patients.Oncoscience · 2015Article
- The E2F transcription factors regulate tumor development and metastasis in a mouse model of metastatic breast cancer.Molecular and cellular biology · 2014Article
- A genomic analysis of mouse models of breast cancer reveals molecular features of mouse models and relationships to human breast cancer.Breast cancer research : BCR · 2014Article
- Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets.Cancer discovery · 2014Article
- Molecular characterization of basal-like and non-basal-like triple-negative breast cancer.The oncologist · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Expression of c-Myc is highly prevalent in human breast cancer and stability of the oncoprotein is regulated through Ras-regulated phosphorylation at serine 62 and threonine 58. Previous studies have illustrated the importance of accumulation of KRas mutations in Myc-mediated tumor formation. To examine Myc dependence upon Ras mutations we have generated MMTV regulated Myc and Myc T58A transgenic mice. Expression of the more stable T58A Myc allele resulted in a reduction in KRas-activating mutations. However, in a low-level expression T58A Myc transgenic, the majority of the tumors were squamous or epithelial-to-mesenchymal in nature and accumulated KRas mutations at a higher frequency. Interestingly, we show that these mice develop similar gene expression patterns and signaling pathway utilization as a subtype of human claudin-low breast cancer. Indeed, our results demonstrate a clear division in human claudin-low tumors based on Myc pathway activation and target genes. Together, our results demonstrate that Myc expression and stability has critical effects on molecular heterogeneity in mouse mammary tumors that parallel subtypes of human breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.